-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Bca4DPtgU9GOTbeFaRrEp+ZKpSypquZ3aD76TSV2gzpbIcogah/mgbnOCGmz6Qng YGOMWCIRoN3viz7GmzAUpg== 0001127602-09-025709.txt : 20091218 0001127602-09-025709.hdr.sgml : 20091218 20091218164633 ACCESSION NUMBER: 0001127602-09-025709 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20091215 FILED AS OF DATE: 20091218 DATE AS OF CHANGE: 20091218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rachman Jonathan CENTRAL INDEX KEY: 0001471222 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15190 FILM NUMBER: 091250585 MAIL ADDRESS: STREET 1: OSI PHARMACEUTICALS, INC. STREET 2: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OSI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000729922 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133159796 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 631-962-2000 MAIL ADDRESS: STREET 1: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: ONCOGENE SCIENCE INC DATE OF NAME CHANGE: 19920703 4 1 form4.xml PRIMARY DOCUMENT X0303 4 2009-12-15 0000729922 OSI PHARMACEUTICALS INC OSIP 0001471222 Rachman Jonathan C/O OSI PHARMACEUTICALS, INC. 41 PINELAWN ROAD MELVILLE NY 11747 1 Sr VP, Diabetes/Obesity R&D Common Stock 2009-12-15 4 A 0 6700 0 A 14904 D Common Stock 2009-12-16 4 F 0 502 32.89 D 14402 D Stock Option (Right to Buy) 35.40 2009-12-15 4 A 0 20000 0 A 2010-12-15 2019-12-14 Common Stock 20000 20000 D Represents the Restricted Stock Unit component of the annual equity compensation to executive officers. 25% of the Restricted Stock Units vest one year after the date of grant and the remainder will vest ratably on an annual basis over the succeeding 3 years. The Reporting Person will receive one share of OSI Common Stock upon the vesting of each Restricted Stock Unit. Reflects the withholding of shares by the Company to satisfy the tax liability upon the vesting of Restricted Stock Units. 25% of the option will become exerciseable one year after the date of grant and the remainder will vest ratably on an annual basis over the succeeding 3 years. Includes only options with the same termination date. /s/ Pierre Legault, attorney-in-fact for Dr. Rachman 2009-12-18 -----END PRIVACY-ENHANCED MESSAGE-----